Blogs about: Erbb1
Featured Blog
Boehringer Ingelheim provide update on kinase programs
Boehringer have provided a pipeline update including information on kinase inhibitors, and announces forthcoming presentations: BIBW 2992 (Tovok) – EGFR/HER2 – Phase III study in NSCLC has… more →
Kinase News
Boehringer Ingelheim provide update on kinase programs
crimsoncanary wrote 1 year ago: Boehringer have provided a pipeline update including information on kinase inhibitors, and announces … more →
Avastin and Tarceva combo does not meet primary endpoint in Phase III NSCLC
crimsoncanary wrote 1 year ago: Phase III trial results show treatment with Avastin/Tarceva in patients with advanced NSCLC did not … more →
Genentech/OSI issue hepatic safety warning for Tarceva
crimsoncanary wrote 1 year ago: OSI and Genentech have notified healthcare professionals that cases of hepatic failure and hepatoren … more →
E Mercks Matuzumab effective in pancreatic cell lines/models
crimsoncanary wrote 1 year ago: E Mercks Matuzumab (EMD72000) reduced ErbB-1 phosphorylation and downstream MAPK and AKT signaling i … more →
Tarceva as salvage treatment in NSCLC following geftinib failure
crimsoncanary wrote 1 year ago: Data publsihed in the Annals of Oncology show that Tarceva (erlotinib) salvage therapy can be an op … more →
Pfizer publish data on pan-erbB receptor tyrosine kinase inhibitor PF-00299804
crimsoncanary wrote 1 year ago: Pfizer have published data on PF-00299804, a second-generation irreversible pan-erbB receptor kinase … more →
Coadministration of CDK inhibitor seliciclib with EGFR inhibitors increases activity
crimsoncanary wrote 1 year ago: Studies published by Cyclacel on the coadministration of CDK inhibitor seliciclib with EGFR/HER2 inh … more →
Biomarkers of clinical benefit associate with erlotinib treatment in NSCLC
crimsoncanary wrote 1 year ago: An analysis of biomarkers in patients treated with erlotinib and platinum therapy in non small cell … more →
Novatis EGFR/VEGFR inhibitor AEE788 preclinical data
crimsoncanary wrote 1 year ago: Novartis have published preclinical information on its EGFR/VEGFR inhibitor AEE788 in the New Engla … more →
Phase IV results show Tarceva lengthens survival and improves QoL
crimsoncanary wrote 1 year ago: New Phase IV data presented at ASCO 2008 show that non-small cell lung cancer (NSCLC) patients treat … more →
Cyclacel initiate Phase I combination study of Seliciclib and Tarceva
crimsoncanary wrote 1 year ago: Cyclacel and the Vall d’Hebron University Hospital have initiated a Phase I trial of Cyclacel’ … more →
